
معرفی
Ximing Yuan is an Adjunct Professor at Linköping University, affiliated with the Faculty of Medicine and Health Sciences (MEDFAK) and the Department of Health, Medicine and Caring Sciences (HMV), specifically within the Division of Prevention, Rehabilitation and Community Medicine (PRNV). He is also a Chief Physician in Occupational and Environmental Medicine at Linköping University Hospital. His primary research focuses on gender disparities in atherosclerotic cardiovascular disease and work-related asthma, emphasizing the role of environmental exposures and real-time lung function monitoring. He teaches in the medical program and related disciplines at Linköping University since 1997.
Research Interests: Dr. Yuan’s work explores biological differences between genders in cardiovascular disease outcomes, including mechanisms driving disparities in diagnosis, treatment, and long-term sick leave. In asthma research, his team develops digital tools like the Asthma Tuner app to map workplace exposures and lung function changes. These projects aim to improve clinical care and occupational health outcomes.
Publications: His recent studies include investigations into hepcidin expression in carotid atheroma, environmental toxin effects on cellular pathways, and proteomic analyses of plaque heterogeneity. These contributions highlight his expertise in vascular biology, environmental medicine, and translational research.
Awards: No scientific awards explicitly mentioned in the provided materials.
Advising & Grants: While no specific grants are detailed, his research collaborations involve multi-disciplinary teams addressing cardiovascular and respiratory health issues. He contributes to clinical trials and translational projects, such as the Asthma Tuner initiative.
Labs/Teams: Active within the Division of Prevention, Rehabilitation and Community Medicine, collaborating with departments like the Division of Diagnostics and Specialist Medicine (DISP) on projects like the study of ectopic fat storage and cardiovascular risk.



